OR WAIT null SECS
© 2021 MJH Life Sciences and Formulary Watch. All rights reserved.
© 2021 MJH Life Sciences™ and Formulary Watch. All rights reserved.
August 01, 2012
The introduction of the immunomodulatory drugs and bortezomib, a proteasome inhibitor, has dramatically improved outcomes in patients with relapsed or refractory multiple myeloma.